Durable Response to Thalidomide-Based Drug Therapy for Myelofibrosis with Myeloid Metaplasia

Mesa, Ruben A.; Elliott, Michelle A.; Schroeder, Georgene; Tefferi, Ayalew
July 2004
Mayo Clinic Proceedings;Jul2004, Vol. 79 Issue 7, p883
Academic Journal
Objective: To present the results of a long-term analysis of 2 sequential phase 2 trials of thalidomide (alone or in combination) for palliation of myelofibrosis with myeloid metaplasia (MMM). Patients and methods: We analyzed (March 1999 to August 2003) initial and long-term outcomes from 36 patients with symptomatic MMM who had enrolled in either our thalidomide single-agent trial (N=15) or our trial of low-dose thalidomide (50 mg/d) combined with predinisone (n=21). Results: Among the 36 study patients, 20 (56%) showed some improvement in their clinical course. Response rates for specific end points included improvements in anemia (15 of 36 [42%]), thrombocytopenia (10 of 13 [77%]), or splenomegaly (5 of 30 [17%]). The combination of low-dose thalidomide and prednisone, as opposed to single-agent thalidomide, was better tolerated and more efficacious. After a median follow-up of 25 months (range, 20-56 months), 10 of 36 patients (28%) showed an ongoing response, including 8 patients in whom protocol treatment has been discontinued for a median of 21 months (range, 16-31 months). Durable treatment responses were documented for only anemia and thrombocytopenia. Treatment response was not affected by the baseline status of bone marrow fibrosis, angiogenesis, osteosclerosis, cytogenetics, or circulating myeloid progenitor (CD34) cell count. Unusual drug effects, all reversible, included leukocytosis (8 patients) and/or thrombocytosis (6 patients). CONCLUSIONS: Thalidomide (alone or combined with prednisone) is an effective first-line treatment of symptomatic anemia or thrombocytopenia in MMM. Thalidomide-based therapy has the potential to produce durable responses in MMM-associated cytopenias, even after discontinuation of the drug.


Related Articles

  • Myelofibrosis: Thalidomide Finds a New Disease. Silver, Richard T. // Mayo Clinic Proceedings;Jul2004, Vol. 79 Issue 7, p857 

    Editorial. Comments on a study on the long-term outcome of thalidomide treatment of myelofibrosis with myeloid metaplasia. Mechanism of action of thalidomide; Responses in the cellular phase of the condition; Therapeutic contribution in terms of quality of life.

  • CORRIGENDUM.  // Biologics: Targets & Therapy;2013, Vol. 7, p231 

    A correction to the article "Treatment and management of myelofibrosis in the era of JAK inhibitors," by C. Keohane, D. H. Radia, and C. N. Harrison that was published in the issue is presented.

  • Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. Richardson, Paul; Schlossman, Robert; Jagannath, Sundar; Alsina, Melissa; Desikan, Raman; Blood, Emily; Weller, Edie; Mitsiades, Constantine; Hideshima, Teru; Davies, Faith; Doss, Deborah; Freeman, Andrea; Bosch, Joan; Patin, John; Knight, Robert; Zeldis, Jerome; Dalton, William; Anderson, Kenneth // Mayo Clinic Proceedings;Jul2004, Vol. 79 Issue 7, p875 

    Objective: To determine the progression-free survival at 12 weeks, to evaluate the toxic effects, and to analyze the biological activity of thalidomide in patients with relapsed multiple myeloma (MM) after high-dose chemotherapy and stem cell transplantation. Patients and Methods: From 1999 to...

  • Régression clinique complète d'une lésion gingivo-mandibulaire de myélome multiple après chimiothérapie exclusive associant dexaméthasone et lénalidomide. A propos d'un cas. Even, Jennifer; LeGoubey, Capucine; Sudrat, Yannick; Devoize, Laurent // Médecine Buccale Chirurgie Buccale;2013, Vol. 19 Issue 2, p113 

    We present the case of a 55 year-old woman with advanced IgA lamba multiple myeloma who developed a mandibular gingival plasmacytoma. Therapeutic solutions are limited, conventional treatments had been all exhausted; it is decided to make an exclusive chemotherapy with a combination of...

  • Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Tuchman, S. A.; Chao, N. J.; Gasparetto, C. G. // Advances in Hematology;2012, p1 

    No abstract available.

  • JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. Harrison, Claire; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni // New England Journal of Medicine;3/1/2012, Vol. 366 Issue 9, p787 

    Background: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. Methods: We assigned 219 patients with...

  • Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Pardanani, A // Leukemia (08876924);Jul2012, Vol. 26 Issue 7, p1449 

    The author discusses the pros and cons of ruxolitinib for the treatment of myelofibrosis. The author mentions a clinical trial which supports that ruxolitinib could be the best available therapy for the management of the said disease. The author states that short-term and long-term...

  • Database study of lenalidomide (Revlimid®) in Germany: monitoring off-label use. Dörks, Michael; Langner, Ingo; Behr, Sigrid; Timmer, Antje; Garbe, Edeltraut // GMS Medizinische Informatik, Biometrie und Epidemiologie;2013, Vol. 9 Issue 3, p1 

    Background: Lenalidomide, a derivate of thalidomide, in combination with dexamethasone is indicated for the treatment of multiple myeloma in patients who have received at least one prior therapy. In the USA, lenalidomide is also licensed for the treatment of a certain form of myelodysplastic...

  • Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma. Alegre, Adrian; Vicua, Isabel; Aguado, Beatriz // Clinical Medicine Insights: Oncology;2012, Issue 6, p1 

    Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics